Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4652 Clinical response to somatostatin analogues in patients with DIPNECH: Findings from a new longitudinal registry

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) often presents with symptoms of cough and dyspnoea. DIPNECH remains understudied, and response to somatostatin analogues (SSAs) has been reported in a few small series.

Conference:

Presenting Author: Libre M

Authors: Libre M, Skotte E, Linden A, Wu J, Lippincott E,

Keywords: DIPNECH, somatostatin analogue,

#4599 Endosonography guided coloenterostomy for management of malignant small bowel ileus

Introduction: Small-bowel ileus (SBI) is often decisive for the prognosis in midgut neuroendocrine tumours (NET) and other peritoneally metastasised neoplasias. Conventional procedures of palliative care deliver unsatisfying results.

Conference:

Presenting Author: Weich A

Authors: Weich A, Retzbach L, Hartung V, Brand M, Kudlich T,

Keywords: Coloenterostomy, Endosonography, small bowel ileus, peritoneal carcinomatosis, midgut NET,

#4579 Real-world effectiveness of lanreotide autogel in patients with advanced gastroenteropancreatic neuroendocrine tumours with antigen Ki-67 proliferation index above and below 10%: The KINETICS study

Introduction: The somatostatin analogue lanreotide is an established treatment option for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a Ki-67 proliferation index (Ki-67)

Conference:

Presenting Author: Vandamme T

Authors: Vandamme T, Gerard L, Del Olmo-Garcia M, de Mestier L, Kiesewetter B,

Keywords: effectiveness, gastroenteropancreatic neuroendocrine tumour, GEP-NET, Ki-67 proliferation index, Ki-67, lanreotide, somatostatin analogue, somatostatin, real-world,

#4470 Demystifying DIPNECH: Updates from a new longitudinal patient registry

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) was first characterised in 1992 with a case series describing 6 patients with neuroendocrine cell hyperplasia, with cough and dyspnoea. Since that time, DIPNECH has remained understudied.

Conference:

Presenting Author:

Authors: Skotte E, Linden A, Libre M, Lippincott E, Cass A,

Keywords: DIPNECH,